SEARCH

SEARCH BY CITATION

REFERENCES

  • 1
    Bryan C, Howard Y, Brennan P, Black C, Silman A. Survival following the onset of scleroderma: results from a retrospective inception cohort study of the UK patient population. Br J Rheumatol 1996; 35: 11226.
  • 2
    Bu-Shakra M, Lee P. Mortality in systemic sclerosis: a comparison with the general population. J Rheumatol 1995; 22: 21002.
  • 3
    Mayes MD, Lacey JV Jr, Beebe-Dimmer J, Gillespie BW, Cooper B, Laing TJ, et al. Prevalence, incidence, survival, and disease characteristics of systemic sclerosis in a large US population. Arthritis Rheum 2003; 48: 224655.
  • 4
    Medsger TA Jr, Masi AT, Rodnan GP, Benedek TG, Robinson H. Survival with systemic sclerosis (scleroderma): a life-table analysis of clinical and demographic factors in 309 patients. Ann Intern Med 1971; 75: 36976.
  • 5
    Steen VD, Medsger TA. Changes in causes of death in systemic sclerosis, 1972–2002. Ann Rheum Dis 2007; 66: 9404.
  • 6
    Altman RD, Medsger TA Jr, Bloch DA, Michel BA. Predictors of survival in systemic sclerosis (scleroderma). Arthritis Rheum 1991; 34: 40313.
  • 7
    Bennett R, Bluestone R, Holt PJ, Bywaters EG. Survival in scleroderma. Ann Rheum Dis 1971; 30: 5818.
  • 8
    Bryan C, Knight C, Black CM, Silman AJ. Prediction of five-year survival following presentation with scleroderma: development of a simple model using three disease factors at first visit. Arthritis Rheum 1999; 42: 26605.
  • 9
    Ferri C, Valentini G, Cozzi F, Sebastiani M, Michelassi C, La MG, et al. Systemic sclerosis: demographic, clinical, and serologic features and survival in 1,012 Italian patients. Medicine (Baltimore) 2002; 81: 13953.
  • 10
    Ioannidis JP, Vlachoyiannopoulos PG, Haidich AB, Medsger TA Jr, Lucas M, Michet CJ, et al. Mortality in systemic sclerosis: an international meta-analysis of individual patient data. Am J Med 2005; 118: 210.
  • 11
    Kaburaki J, Lee CC, Kuwana M, Tojo T, Ikeda Y, Takano M, et al. Initial predictors of survival in patients with systemic sclerosis (scleroderma). Keio J Med 1992; 41: 1415.
  • 12
    Nagy Z, Czirjak L. Predictors of survival in 171 patients with systemic sclerosis (scleroderma). Clin Rheumatol 1997; 16: 45460.
  • 13
    Scussel-Lonzetti L, Joyal F, Raynauld JP, Roussin A, Rich E, Goulet JR, et al. Predicting mortality in systemic sclerosis: analysis of a cohort of 309 French Canadian patients with emphasis on features at diagnosis as predictive factors for survival. Medicine (Baltimore) 2002; 81: 15467.
  • 14
    Simeon CP, Armadans L, Fonollosa V, Vilardell M, Candell J, Tolosa C, et al. Survival prognostic factors and markers of morbidity in Spanish patients with systemic sclerosis. Ann Rheum Dis 1997; 56: 7238.
  • 15
    Simeon CP, Armadans L, Fonollosa V, Solans R, Selva A, Villar M, et al. Mortality and prognostic factors in Spanish patients with systemic sclerosis. Rheumatology (Oxford) 2003; 42: 715.
  • 16
    Steen VD, Medsger TA Jr. Severe organ involvement in systemic sclerosis with diffuse scleroderma. Arthritis Rheum 2000; 43: 243744.
  • 17
    Arnett FC. HLA and autoimmunity in scleroderma (systemic sclerosis). Int Rev Immunol 1995; 12: 10728.
  • 18
    Reveille JD, Fischbach M, McNearney T, Friedman AW, Aguilar MB, Lisse J, et al. Systemic sclerosis in 3 US ethnic groups: a comparison of clinical, sociodemographic, serologic, and immunogenetic determinants. Semin Arthritis Rheum 2001; 30: 33246.
  • 19
    Langevitz P, Buskila D, Gladman DD, Darlington GA, Farewell VT, Lee P. HLA alleles in systemic sclerosis: association with pulmonary hypertension and outcome. Br J Rheumatol 1992; 31: 60913.
  • 20
    McNearney TA, Reveille JD, Fischbach M, Friedman AW, Lisse JR, Goel N, et al. Pulmonary involvement in systemic sclerosis: associations with genetic, serologic, sociodemographic, and behavioral factors. Arthritis Rheum 2007; 57: 31826.
  • 21
    Subcommittee for Scleroderma Criteria of the American Rheumatism Association Diagnostic and Therapeutic Criteria Committee. Preliminary criteria for the classification of systemic sclerosis (scleroderma). Arthritis Rheum 1980; 23: 58190.
  • 22
    Clements P, Lachenbruch P, Siebold J, White B, Weiner S, Martin R, et al. Inter and intraobserver variability of total skin thickness score (modified Rodnan TSS) in systemic sclerosis. J Rheumatol 1995; 22: 12815.
  • 23
    Medsger TA Jr, Silman AJ, Steen VD, Black CM, Akesson A, Bacon PA, et al. A disease severity scale for systemic sclerosis: development and testing. J Rheumatol 1999; 26: 215967.
  • 24
    Chobanian AV, Bakris GL, Black HR, Cushman WC, Green LA, Izzo JL Jr, et al. Seventh report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure. Hypertension 2003; 42: 120652.
  • 25
    WHO Expert Consultation. Appropriate body-mass index for Asian populations and its implications for policy and intervention strategies. Lancet 2004; 363: 15763.
  • 26
    Pellegrino R, Viegi G, Brusasco V, Crapo RO, Burgos F, Casaburi R, et al. Interpretative strategies for lung function tests. Eur Respir J 2005; 26: 94868.
  • 27
    Hosmer DW, Lemeshow S. Applied survival analysis: regression modeling of time to event data. New York: John Wiley & Sons; 1999. p. 15980.
  • 28
    Leroy EC, Black C, Fleischmajer R, Jablonska S, Krieg T, Medsger TA Jr, et al. Scleroderma (systemic sclerosis): classification, subsets and pathogenesis. J Rheumatol 1988; 15: 2025.
  • 29
    Krishnan E, Furst DE. Systemic sclerosis mortality in the United States: 1979–1998. Eur J Epidemiol 2005; 20: 85561.
  • 30
    Mendoza F, Derk CT. Systemic sclerosis mortality in the United States: 1999–2002 implications for patient care. J Clin Rheumatol 2007; 13: 18792.
  • 31
    Nietert PJ, Silver RM, Mitchell HC, Shaftman SR, Tilley BC. Demographic and clinical factors associated with in-hospital death among patients with systemic sclerosis. J Rheumatol 2005; 32: 188892.
  • 32
    Hsu VM, Moreyra AE, Wilson AC, Shinnar M, Shindler DM, Wilson JE, et al. Assessment of pulmonary arterial hypertension in patients with systemic sclerosis: comparison of noninvasive tests with results of right-heart catheterization. J Rheumatol 2008; 35: 45865.
  • 33
    Cowper DC, Kubal JD, Maynard C, Hynes DM. A primer and comparative review of major US mortality databases. Ann Epidemiol 2002; 12: 4628.
  • 34
    Pritt BS, Hardin NJ, Richmond JA, Shapiro SL. Death certification errors at an academic institution. Arch Pathol Lab Med 2005; 129: 14769.
  • 35
    Ravakhah K. Death certificates are not reliable: revivification of the autopsy. South Med J 2006; 99: 72833.
  • 36
    Khoury MJ. Commentary: epidemiology and the continuum from genetic research to genetic testing. Am J Epidemiol 2002; 156: 2979.
  • 37
    Yang Q, Khoury MJ. Evolving methods in genetic epidemiology. III. Gene-environment interaction in epidemiologic research. Epidemiol Rev 1997; 19: 3343.
  • 38
    Kang SH, Park MH, Song EY, Kang SJ, Lee EB, Song YW, et al. Association of HLA class II genes with systemic sclerosis in Koreans. J Rheumatol 2001; 28: 157783.
  • 39
    Arnett FC, Gourh P, Shete S, Ahn CW, Honey R, Agarwal SK, et al. Major histocompatibility complex (MHC) class II alleles, haplotypes, and epitopes which confer susceptibility or protection in the fibrosing autoimmune disease systemic sclerosis: analysis in 1,300 Caucasian, African American and Hispanic cases and 1,000 controls. Ann Rheum Dis 2009. E-pub ahead of print.
  • 40
    Lambert NC, Distler O, Muller-Ladner U, Tylee TS, Furst DE, Nelson JL. HLA–DQA1*0501 is associated with diffuse systemic sclerosis in Caucasian men. Arthritis Rheum 2000; 43: 200510.
  • 41
    Arnett FC, Howard RF, Tan F, Moulds JM, Bias WB, Durban E, et al. Increased prevalence of systemic sclerosis in a Native American tribe in Oklahoma: association with an Amerindian HLA haplotype. Arthritis Rheum 1996; 39: 136270.